Not good news for people taking Adderall XR or Dexedrine this morning.
GlaxoSmithKline Plc and Shire Plc said they strengthened warnings that their attention-deficit drugs may cause psychological side effects and misuse may lead to sudden death from heart attacks and strokes.
Glaxo, the world’s second-largest drugmaker, said today that it added the warnings to prescribing information on its Dexedrine treatment last month. Shire said it also added the warnings for its Adderall XR, the top-selling treatment for attention deficit hyperactivity disorder.
Source: Bloomberg.com: U.K.
Dr. John Grohol is the CEO and founder of Psych Central. He is an author, researcher and expert in mental health online, and has been writing about online behavior, mental health and psychology issues -- as well as the intersection of technology and human behavior -- since 1992. Dr. Grohol sits on the editorial board of the journal Cyberpsychology, Behavior and Social Networking and is a founding board member and treasurer of the Society for Participatory Medicine.Like this author?
Catch up on other posts by John M. Grohol, PsyD (or subscribe to their feed).
Comments
This post currently has 4 comments. You can read the comments or leave your own thoughts on our new comments page.
Trackbacks
No trackbacks yet to this post.
Last reviewed: By John M. Grohol, Psy.D. on 22 Aug 2006
Published on PsychCentral.com. All rights reserved.
Grohol, J. (2006). Glaxo, Shire Strengthen Risk Warnings on ADHD Drugs. Psych Central. Retrieved on May 25, 2012, from http://psychcentral.com/blog/archives/2006/08/22/glaxo-shire-strengthen-risk-warnings-on-adhd-drugs/
